IO Biotech’s Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year

All NewsAugust 11, 2025

IO Biotech’s Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across most subgroups.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent